Nuvectis Pharma(NVCT) - 2025 Q3 - Quarterly Report

Financial Performance and Expectations - The company has incurred losses since its inception and has not generated any revenue, expecting continued losses for the foreseeable future[11]. - The company will require substantial additional capital to finance its operations and achieve its goals, which may lead to delays or reductions in research and development if capital is not raised[11]. - The company does not intend to pay dividends on its common stock in the foreseeable future, limiting returns to stock value appreciation[17]. Product Development and Regulatory Risks - The company is substantially dependent on the success of its product candidate, NXP900, which is still in the development phase[11]. - The company has initiated a limited number of clinical trials with a small number of patients currently enrolled, with no completed trials to date[11]. - The development and commercialization of pharmaceutical products are subject to extensive regulation, and the company may not obtain necessary regulatory approvals for its product candidates[11]. - Clinical trials are expensive and time-consuming, with uncertain outcomes that may not predict future results[11]. - The company faces risks related to the manufacturing of its product candidates, which may encounter difficulties or interruptions[14]. Operational and Organizational Aspects - The company currently has 13 full-time employees and plans to grow its organization to meet operational needs[17]. External Factors - Tariffs and other trade measures could adversely affect the company's business, results of operations, financial position, and cash flows[11].